2961-3035. 2. Peppercorn M A. Sulfasalazine: pharmacology, clinical use, toxicity and related new drug development. Ann Intern Med 1984: 101: 377-386. 3. Pullar T, Hunter J A, Capell H A. Sulfasalazine in rheumatoid arthritis: a double blind comparison of sulfasalazine with placebo and sodium aurothiomalate. Br Med J 1983: 287: 1102-1104. 4. Das K M, Eastwood M A, McManus J P A, Sircus W. Adverse reactions during salicylazosulfapyridine therapy SHORT COMMUNICATIONS and the relation with drug metabolism and acetylator phenotype. N Eng! J Med 1973: 289: 491-495. 5. Kanwar A J, Singh M, Yunus M, Belhaj M S. Fixed eruption to sulphasalazine. Dermatologica 1987: 174: 104. 6. Udono M, Murayama F, Tanioka H. Fixed drug eruption due to salazosulfapyridine and fixed drug eruption due to mefenamic acid. Medical Achievements of Sasebo City Hospital (in Japanese) 1991: 17: 57-61. 7. Hertl M, Jugert F, Merk H F. CDS+ dermal T cells from a sulphamethoxazole-induced bullous exanthem proliferate in response to drug-modified liver microsomes. Br J Dermato/1995: 132: 215-220. 8. Hayllar J, Bjarnason I. Sulphasalazine in ulcerative colitis: in memoriam?

No abstract

No abstract

This paper reports a case study of a 10-year-old girl exhibiting symptoms of a Zimmermann-Laband syndrome (ZLS), including an ocular involvement not previously observed. In addition to the case reported, we have also discovered 21 patients described in the literature. Major clinical findings, defined as being present in more than 75% of the cases under discussion, are presented.